InfectoTest GmbH is excited to announce a strategic investment from Biocomposites, supporting the development of InfectoSynovia – a cutting-edge, high-accuracy point-of-care test designed to diagnose periprosthetic joint infections (PJI) in under 5 minutes.

InfectoSynovia utilizes an innovative electrochemical analysis method, requiring only a minimal sample of synovial fluid. This breakthrough technology aims to revolutionize the diagnosis of PJI, addressing a growing global need as joint replacements rise with ageing populations. Biocomposites' investment reflects their commitment to advancing infection management in bone and soft tissue, further strengthening their portfolio of innovative solutions.

InfectoTest GmbH is very pleased to anticipate a close and productive collaboration with Biocomposites in the future.

For more information on this exciting partnership and our shared dedication to infection management, please refer to the full press release.